Search

GlaxoSmithKline PLC

Închisă

SectorSănătate

1,779 -0.39

Rezumat

Modificarea prețului

24h

Curent

Minim

1766

Maxim

1786

Indicatori cheie

By Trading Economics

Venit

-126M

1.6B

Vânzări

470M

8B

P/E

Medie Sector

13.211

77.256

EPS

0.55

Randament dividend

3.59

Marjă de profit

20.611

Angajați

68,629

EBITDA

139M

3.2B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-6.42% downside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.59%

2.33%

Data viitoare de dividende

8 ian. 2026

Următoarea dată ex-dividende

13 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

14B

71B

Deschiderea anterioară

1779.39

Închiderea anterioară

1779

Sentimentul știrilor

By Acuity

35%

65%

112 / 374 Clasament în Healthcare

GlaxoSmithKline PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 oct. 2025, 11:28 UTC

Câștiguri

GSK Lifts Guidance After Specialty Medicines Boost Sales -- Update

29 oct. 2025, 08:11 UTC

Câștiguri

GSK Raises Guidance After Sales, Earnings Growth

1 oct. 2025, 08:54 UTC

Principalele dinamici ale pieței

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

29 oct. 2025, 13:26 UTC

Market Talk
Câștiguri

GSK's Strong Results Likely to Bolster R&D Spending -- Market Talk

29 oct. 2025, 13:20 UTC

Market Talk

GSK Sales Growth, Pipeline Could Ease Skepticism of Ambitious Sales Goals -- Market Talk

29 oct. 2025, 12:26 UTC

Market Talk
Câștiguri

New GSK Chief to Inherit Healthy Business Despite Trade, Tariff Risks -- Market Talk

29 oct. 2025, 12:15 UTC

Market Talk
Câștiguri

GSK CEO Leaves Group in Good Health as Streamlining Pays off -- Market Talk

29 oct. 2025, 07:10 UTC

Câștiguri

GSK 3Q Adj EPS 55.0p

29 oct. 2025, 07:10 UTC

Câștiguri

GSK 3Q EPS 49.9p

29 oct. 2025, 07:09 UTC

Câștiguri

GSK Had Seen Core Operating Profit Growth of 6% to 8%

29 oct. 2025, 07:09 UTC

Câștiguri

GSK Now Sees Core Operating Profit Growth of 9% to 11%

29 oct. 2025, 07:08 UTC

Câștiguri

GSK Had Seen Core EPS Growth of 6% to 8%

29 oct. 2025, 07:08 UTC

Câștiguri

GSK Now Sees 2025 Core EPS Growth of 10% to 12%

29 oct. 2025, 07:06 UTC

Câștiguri

GSK Had Seen 2025 Sales Growth Toward Top End of 3% to 5% Range

29 oct. 2025, 07:06 UTC

Câștiguri

GSK Now Sees 2025 Sales Growth Between 6% to 7%

29 oct. 2025, 07:05 UTC

Câștiguri

GSK Raises 2025 View

29 oct. 2025, 07:02 UTC

Câștiguri

Analysts Had Seen GSK 3Q Core Operating Profit of GBP2.67B

29 oct. 2025, 07:02 UTC

Câștiguri

GSK 3Q Core Operating Profit GBP2.99B

29 oct. 2025, 07:01 UTC

Câștiguri

Analysts Had Seen GSK 3Q Sales of GBP8.24B

29 oct. 2025, 07:01 UTC

Câștiguri

GSK 3Q Sales GBP8.55B

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q EPS 49.1p

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q Adj EPS 55.0p

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q Turnover GBP8.55B

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q Pre-items, Pretax Pft GBP2.85B

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q Pretax Pft GBP2.46B

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q Oper Pft GBP2.59B

29 oct. 2025, 07:00 UTC

Câștiguri

GSK PLC 3Q Net Pft GBP2.01B

27 oct. 2025, 13:32 UTC

Câștiguri

GSK's Future Strategy in Focus Amid CEO Change -- Earnings Preview

1 oct. 2025, 07:53 UTC

Market Talk

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

30 sept. 2025, 10:48 UTC

Market Talk

GSK's New CEO, Potential Vaccine Spinoff Signal a New Dawn -- Market Talk

GlaxoSmithKline PLC Așteptări

Obiectiv de preț

By TipRanks

-6.42% jos

Prognoză pe 12 luni

Medie 1,673.25 GBX  -6.42%

Maxim 2,250 GBX

Minim 1,345 GBX

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGlaxoSmithKline PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

13 ratings

3

Cumpărare

7

Păstrare

3

Vânzare

Sentiment

By Acuity

112 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat